Wenzhi Tian

机构：NGM Biopharmaceuticals (United States), Peking University Shenzhen Hospital · ORCID：0000-0002-1986-4381

发表论文 87 篇 · 总被引 1663 次 · h-index 19

代表论文

• Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives (2024 · Frontiers in Oncology · 被引 45)
• Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study (2024 · Journal of Hematology & Oncology · 被引 16)
• IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study. (2024 · Journal of Clinical Oncology · 被引 6)
• Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38 (2024 · Frontiers in Immunology · 被引 5)
• IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy (2024 · Heliyon · 被引 4)
• DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways (2024 · Frontiers in Immunology · 被引 4)